Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 222,787,835 papers from all fields of science
Search
Sign In
Create Free Account
Vandetanib
An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Narrower (2)
Caprelsa
ZD 6474
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Vandetanib 300 MG Oral Tablet [Caprelsa]
docetaxel/ZD6474
Broader (1)
Zactima
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Systemic treatment and management approaches for medullary thyroid cancer.
Vinicius Ernani
,
Mukesh Kumar
,
Amy Y. Chen
,
T. Owonikoko
Cancer Treatment Reviews
2016
Corpus ID: 29604619
2015
2015
Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
V. R. Belum
,
Courtney A. Washington
,
C. Pratilas
,
V. Sibaud
,
F. Boralevi
,
M. Lacouture
Pediatric Blood & Cancer
2015
Corpus ID: 35934828
The dermatologic adverse events (AEs) of various molecularly targeted therapies are well‐described in adult cancer patients…
Expand
Review
2013
Review
2013
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
C. Langer
,
T. Mok
,
P. Postmus
Cancer Treatment Reviews
2013
Corpus ID: 25851466
Review
2013
Review
2013
Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study.
T. Rauramaa
,
M. Pikkarainen
,
+4 authors
I. Alafuzoff
Journal of Neuropathology and Experimental…
2013
Corpus ID: 8872968
There is no consensus on the pathologic conditions or severity implied by the term "hippocampal sclerosis" (HS). In this study, a…
Expand
Review
2012
Review
2012
Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.
A. Custodio
,
M. Méndez
,
M. Provencio
Cancer Treatment Reviews
2012
Corpus ID: 24291687
2012
2012
Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
A. Samadi
,
J. Bazzill
,
+6 authors
Mark S. Cohen
Surgery
2012
Corpus ID: 14398371
Review
2010
Review
2010
Molecularly targeted therapy in hepatocellular carcinoma.
H. Huynh
Biochemical Pharmacology
2010
Corpus ID: 205963690
Highly Cited
2009
Highly Cited
2009
Targeting RET for thyroid cancer therapy.
C. Lanzi
,
G. Cassinelli
,
Valentina Nicolini
,
F. Zunino
Biochemical Pharmacology
2009
Corpus ID: 24283489
2009
2009
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
M. Cesca
,
R. Frapolli
,
+6 authors
R. Giavazzi
Neoplasia
2009
Corpus ID: 45079492
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular…
Expand
Review
2006
Review
2006
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
S. Sathornsumetee
,
J. Rich
Drugs of Today
2006
Corpus ID: 20987261
In clinical trials thus far, single-targeted kinase inhibitors have shown only limited success in demonstrating survival benefits…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE